Lorri Darrow, MD
Psychiatry · Springfield, MONPI 1679579593
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,238 of the $47,202 with a category attached, or 76.8%. Otsuka America Pharmaceutical, Inc. accounts for 83.4% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $28,109, more than ten times the $39 reported in 2019. Among psychiatry clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 420 payments — averaging $112.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$39K
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Neurocrine Biosciences, Inc.$759
- Vanda Pharmaceuticals Inc.$751
- Johnson & Johnson$659
- plus $3K from 21 others
What the payments were for
- Speaking & faculty fees$36,23877%
- Travel & lodging$1,3853%
- Food & beverage$9,38620%
- Education$1930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 92 | $39,362 |
| AbbVie(2 entities) | 65 | $1,229 |
| Teva Pharmaceuticals USA, Inc. | 47 | $1,044 |
| Neurocrine Biosciences, Inc. | 30 | $759 |
| Vanda Pharmaceuticals Inc. | 25 | $751 |
| Johnson & Johnson(2 entities) | 16 | $659 |
| Alkermes, Inc. | 20 | $616 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $437 |
| Supernus Pharmaceuticals, Inc. | 23 | $422 |
| Axsome Therapeutics, Inc. | 11 | $420 |
| Lundbeck LLC | 15 | $256 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $250 |
| Napo Pharmaceuticals Inc | 11 | $229 |
| E.r. Squibb & Sons, L.L.C. | 14 | $190 |
| Viiv Healthcare Company | 7 | $131 |
| Gilead | 1 | $90 |
| EMD Serono, Inc. | 4 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $81 |
| Merck | 4 | $58 |
| Lilly USA, LLC | 1 | $22 |
| Dexcom, Inc. | 1 | $20 |
| Neuronetics, Inc. | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Verona Pharma, Inc. | 1 | $14 |
| Organon | 1 | $14 |
| Novo Nordisk | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$32,509
- ABILIFY MAINTENA$5,803
- ABILIFY ASIMTUFII$5,803
- LYBALVI$401
- INVEGA SUSTENNA$252
- INVEGA TRINZA$252
- Auvelity$248
- UZEDY$226
- AUSTEDO$123
- Fanapt$123
- CAPLYTA$110
- INGREZZA$102
How this compares
$47,202 in reported general payments places this provider in the 95th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 61 | $589,334 |
| IngrezzaValbenazine Tosylate | 23 | $189,751 |
| RexultiBrexpiprazole | 121 | $179,717 |
| Invega SustennaPaliperidone Palmitate | 25 | $79,977 |
| LybalviOlanzapine/Samidorphan Malate | 39 | $73,221 |
| VraylarCariprazine Hcl | 44 | $62,542 |
| TrintellixVortioxetine Hydrobromide | 35 | $17,266 |
| VyvanseLisdexamfetamine Dimesylate | 44 | $16,543 |
| Aripiprazole | 127 | $9,544 |
| BelsomraSuvorexant | 13 | $9,387 |
| Paliperidone ErPaliperidone | 40 | $5,478 |
| Lisdexamfetamine Dimesylate | 23 | $3,782 |
| Duloxetine Hcl | 191 | $3,473 |
| Bupropion XlBupropion Hcl | 339 | $3,379 |
| Buspirone Hcl | 209 | $3,206 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $1,044 | $589,33461 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $759 | $189,75123 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $39,362 | $179,717121 claims |
| Johnson & JohnsonInvega Sustenna | $659 | $79,97725 claims |
| Alkermes, Inc.Lybalvi | $616 | $73,22139 claims |
| AbbVieVraylar | $1,229 | $62,54244 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $81 | $33,80979 claims |
| MerckBelsomra | $58 | $9,38713 claims |
| Lilly USA, LLCOlanzapine | $22 | $3,005130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Springfield
- Alok JainSpringfield$64K
- Gregory MattingleySaint Charles$4.7M
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mohd MalikSaint Louis$956K
- Brian BarashKansas City$856K
- Casey ProughLees Summit$615K
- George GrossbergSaint Louis$501K
- Shahid InsafBranson$416K
- Ahmed TaranissiMexico$343K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.